Free Trial

Alpha Pro Tech (APT) Competitors

Alpha Pro Tech logo
$4.78 +0.03 (+0.63%)
As of 07/7/2025 04:00 PM Eastern

APT vs. TLSI, INGN, ELMD, PROF, KRMD, CVRX, LNSR, AVR, PDEX, and RCEL

Should you be buying Alpha Pro Tech stock or one of its competitors? The main competitors of Alpha Pro Tech include TriSalus Life Sciences (TLSI), Inogen (INGN), Electromed (ELMD), Profound Medical (PROF), KORU Medical Systems (KRMD), CVRx (CVRX), LENSAR (LNSR), Anteris Technologies Global (AVR), Pro-Dex (PDEX), and Avita Medical (RCEL). These companies are all part of the "medical equipment" industry.

Alpha Pro Tech vs. Its Competitors

TriSalus Life Sciences (NASDAQ:TLSI) and Alpha Pro Tech (NYSE:APT) are both small-cap medical equipment companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends.

TriSalus Life Sciences has a beta of 0.5, meaning that its stock price is 50% less volatile than the S&P 500. Comparatively, Alpha Pro Tech has a beta of 0.32, meaning that its stock price is 68% less volatile than the S&P 500.

Alpha Pro Tech has higher revenue and earnings than TriSalus Life Sciences. TriSalus Life Sciences is trading at a lower price-to-earnings ratio than Alpha Pro Tech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TriSalus Life Sciences$32.14M5.84-$30.05M-$1.12-4.43
Alpha Pro Tech$58.18M0.89$4.19M$0.3712.92

2.6% of TriSalus Life Sciences shares are owned by institutional investors. Comparatively, 22.7% of Alpha Pro Tech shares are owned by institutional investors. 27.5% of TriSalus Life Sciences shares are owned by company insiders. Comparatively, 15.0% of Alpha Pro Tech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

TriSalus Life Sciences currently has a consensus price target of $10.75, indicating a potential upside of 116.73%. Given TriSalus Life Sciences' stronger consensus rating and higher probable upside, analysts plainly believe TriSalus Life Sciences is more favorable than Alpha Pro Tech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TriSalus Life Sciences
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
2 Strong Buy rating(s)
3.25
Alpha Pro Tech
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Alpha Pro Tech has a net margin of 6.99% compared to TriSalus Life Sciences' net margin of -84.67%. Alpha Pro Tech's return on equity of 6.70% beat TriSalus Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
TriSalus Life Sciences-84.67% N/A -111.63%
Alpha Pro Tech 6.99%6.70%5.76%

In the previous week, Alpha Pro Tech had 1 more articles in the media than TriSalus Life Sciences. MarketBeat recorded 1 mentions for Alpha Pro Tech and 0 mentions for TriSalus Life Sciences. Alpha Pro Tech's average media sentiment score of 0.59 beat TriSalus Life Sciences' score of 0.00 indicating that Alpha Pro Tech is being referred to more favorably in the news media.

Company Overall Sentiment
TriSalus Life Sciences Neutral
Alpha Pro Tech Positive

Summary

Alpha Pro Tech beats TriSalus Life Sciences on 10 of the 17 factors compared between the two stocks.

Get Alpha Pro Tech News Delivered to You Automatically

Sign up to receive the latest news and ratings for APT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

APT vs. The Competition

MetricAlpha Pro TechSurgical appliances & supplies IndustryIndustrials SectorNYSE Exchange
Market Cap$51.93M$28.47M$7.57B$20.71B
Dividend YieldN/AN/A4.53%3.72%
P/E Ratio12.9212.9224.8127.80
Price / Sales0.892.43117.6347.12
Price / Cash12.8012.8026.6518.22
Price / Book0.902.364.344.59
Net Income$4.19M-$5.31M$790.28M$982.91M
7 Day Performance0.21%2.23%1.81%0.65%
1 Month Performance4.82%-6.88%4.77%4.26%
1 Year Performance-14.18%-3.66%31.22%13.93%

Alpha Pro Tech Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
APT
Alpha Pro Tech
1.4777 of 5 stars
$4.78
+0.6%
N/A-16.4%$51.93M$58.18M12.92120
TLSI
TriSalus Life Sciences
2.6126 of 5 stars
$5.45
+2.4%
$10.75
+97.2%
-14.6%$201.30M$29.43M-4.87106High Trading Volume
INGN
Inogen
4.3835 of 5 stars
$7.03
-0.7%
$11.00
+56.5%
-12.0%$190.36M$335.70M-6.111,030
ELMD
Electromed
1.4762 of 5 stars
$21.99
flat
$38.00
+72.8%
+41.6%$184.41M$61.44M29.32160
PROF
Profound Medical
2.6542 of 5 stars
$5.90
-1.7%
$11.50
+94.9%
-31.6%$180.32M$10.68M-4.84150
KRMD
KORU Medical Systems
2.1792 of 5 stars
$3.58
-1.4%
$4.50
+25.7%
+45.6%$167.49M$33.65M-32.5580News Coverage
Positive News
High Trading Volume
CVRX
CVRx
2.7127 of 5 stars
$5.88
+1.0%
$14.50
+146.6%
-46.7%$151.74M$51.29M-2.70160Positive News
LNSR
LENSAR
1.3568 of 5 stars
$13.17
+3.2%
$15.00
+13.9%
+187.2%$150.47M$53.49M-2.72110
AVR
Anteris Technologies Global
N/A$3.79
-6.7%
$16.50
+335.4%
N/A$146.41M$2.70M0.00138Positive News
PDEX
Pro-Dex
2.4553 of 5 stars
$43.64
-2.8%
$56.00
+28.3%
+164.9%$146.36M$53.84M15.59140High Trading Volume
RCEL
Avita Medical
0.8507 of 5 stars
$5.29
-2.9%
$16.50
+211.9%
-35.9%$144.07M$64.25M-2.42130

Related Companies and Tools


This page (NYSE:APT) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners